The Efficacy and Safety of Hydroxychloroquine for COVID-19 Prophylaxis and Clinical Assessment: an Updated Meta-analysis of Randomized Trials

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2024 Jun 17

PMID 38883686

Authors

Xudong Han

Wei Shi

Ya Yang

Affiliations

Soon will be listed here.

Abstract

Background: Coronavirus disease 2019 (COVID-19), a disease that affected tens of millions of people, upended the lives of countless individuals around the globe. The chloroquine (CQ) and its analogue hydroxychloroquine (HCQ) were the most frequently cited as potential treatments and preventatives against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The primary aim of this investigation was to scrutinize the effectiveness and safety of HCQ for COVID-19 prevention and to present powerful evidence and reference for clinical practice.

Methods: PubMed, Ovid and the Cochrane COVID-19 Register of Controlled Trials (CENTRAL) were systematically searched from inception to January 31, 2022. Randomized controlled trials (RCTs) trials that included participants who were SARS-CoV-2 negative at the time of registration were enrolled in this meta-analysis. The intervention group took HCQ or CQ orally. The control group was not blinded by quinine or placebo. Pooled relative risk (RR) of SARS-CoV-2 infection, mortality, hospitalization, adverse events, and compliance were calculated. The software tools utilized for statistical analyses were Stata 14 and Review Manager 5.3.

Results: A total of 9 studies including 7,825 participants were enrolled. Bias of individual studies were assessed as low risk. The pooled RR for SARS-CoV-2 infection was 0.75 [95% confidence interval (CI): 0.68-0.83] (z=-4.01, P<0.0001; I=11%). The pooled RR for hospitalization was 0.72 (95% CI: 0.35-1.50) (z=0.87, P=0.39; I=0.0%). The pooled RR for mortality and adverse events were 3.26 (95% CI: 0.13-79.74) (z=0.72, P=0.47; I=0.0%) and 1.90 (95% CI: 1.20-3.02) (z=2.73, P=0.0063; I=94%).

Conclusions: Results of this meta-analysis indicated significant impact of HCQ on SARS-CoV-2 infection with higher risk of adverse events. These findings must be considered with caution, and further research is necessary to delineate the specific circumstances where HCQ may be effective for COVID-19 prevention.

References

Schrezenmeier E, Dorner T . Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020; 16(3):155-166. DOI: 10.1038/s41584-020-0372-x. View

Kumar M, Al Khodor S . Pathophysiology and treatment strategies for COVID-19. J Transl Med. 2020; 18(1):353. PMC: 7491044. DOI: 10.1186/s12967-020-02520-8. View

Garcia-Albeniz X, Del Amo J, Polo R, Morales-Asencio J, Hernan M . Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19. Eur J Epidemiol. 2022; 37(8):789-796. PMC: 9360718. DOI: 10.1007/s10654-022-00891-4. View

Deming M, Chen W . COVID-19 and Lessons to Be Learned from Prior Coronavirus Outbreaks. Ann Am Thorac Soc. 2020; 17(7):790-794. PMC: 7328171. DOI: 10.1513/AnnalsATS.202002-149PS. View

Seet R, Quek A, Ooi D, Sengupta S, Lakshminarasappa S, Koo C . Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. Int J Infect Dis. 2021; 106:314-322. PMC: 8056783. DOI: 10.1016/j.ijid.2021.04.035. View

Mitja O, Corbacho-Monne M, Ubals M, Alemany A, Suner C, Tebe C . A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. N Engl J Med. 2020; 384(5):417-427. PMC: 7722693. DOI: 10.1056/NEJMoa2021801. View

Grau-Pujol B, Camprubi-Ferrer D, Marti-Soler H, Fernandez-Pardos M, Carreras-Abad C, Velasco-de Andres M . Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial. Trials. 2021; 22(1):808. PMC: 8591593. DOI: 10.1186/s13063-021-05758-9. View

Singh H, Chauhan P, Kakkar A . Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead. Eur J Pharmacol. 2020; 890:173717. PMC: 7606072. DOI: 10.1016/j.ejphar.2020.173717. View

Zhou G, Verweij S, Bijlsma M, de Vos S, Oude Rengerink K, Pasmooij A . Repurposed drug studies on the primary prevention of SARS-CoV-2 infection during the pandemic: systematic review and meta-analysis. BMJ Open Respir Res. 2023; 10(1). PMC: 10462970. DOI: 10.1136/bmjresp-2023-001674. View

10.

Zeouk I, Bekhti K, Lorenzo-Morales J . From Wuhan to COVID-19 Pandemic: An Up-to-Date Review of Its Pathogenesis, Potential Therapeutics, and Recent Advances. Microorganisms. 2020; 8(6). PMC: 7355460. DOI: 10.3390/microorganisms8060850. View

11.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

12.

Weston S, Coleman C, Haupt R, Logue J, Matthews K, Li Y . Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 and SARS-CoV . J Virol. 2020; 94(21). PMC: 7565640. DOI: 10.1128/JVI.01218-20. View

13.

McKinnon J, Wang D, Zervos M, Saval M, Marshall-Nightengale L, Kilgore P . Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study. Int J Infect Dis. 2021; 116:167-173. PMC: 8695310. DOI: 10.1016/j.ijid.2021.12.343. View

14.

Rodrigo C, Fernando S, Rajapakse S . Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review. Clin Microbiol Infect. 2020; 26(8):979-987. PMC: 7250111. DOI: 10.1016/j.cmi.2020.05.016. View

15.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

16.

Zhou D, Dai S, Tong Q . COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020; 75(7):1667-1670. PMC: 7184499. DOI: 10.1093/jac/dkaa114. View

17.

Hong H, Friedland A, Hu M, Anstrom K, Halabi S, McKinnon J . Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials. BMJ Open. 2023; 13(6):e065305. PMC: 10276967. DOI: 10.1136/bmjopen-2022-065305. View

18.

DerSimonian R, Laird N . Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015; 45(Pt A):139-45. PMC: 4639420. DOI: 10.1016/j.cct.2015.09.002. View

19.

Bartoszko J, Siemieniuk R, Kum E, Qasim A, Zeraatkar D, Diaz Martinez J . Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ. 2021; 373:n949. PMC: 8073806. DOI: 10.1136/bmj.n949. View

20.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View